IVVD

Invivyd, Inc.

A biopharmaceutical company making monoclonal antibody medicines for viral diseases, Invivyd's only commercial product is PEMGARDA (pemivibart), a preventive antibody given to certain immunocompromised adults and teens at risk of COVID-19. It was founded in 2020 as Adagio Therapeutics, a spin-out of the antibody-discovery firm Adimab, and renamed Invivyd in 2022. The name hints at its mission of building antibodies that outpace fast-mutating viruses.

CUSIP: 00534A102HealthcareUS1 holder

Ownership Activity Financials Filings

IVVD

IVVD

Results of Operations and Financial Condition

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Other Events

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Other Events

Results of Operations and Financial Condition

Results of Operations and Financial Condition